IDH1 MUTATION
Clinical trials for IDH1 MUTATION explained in plain language.
Never miss a new study
Get alerted when new IDH1 MUTATION trials appear
Sign up with your email to follow new studies for IDH1 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Drug attack on Tough-to-Treat leukemia shows early promise
Disease control Recruiting nowThis study is testing a new combination of three drugs (venetoclax, ivosidenib, and azacitidine) for adults with a specific genetic form of acute myeloid leukemia (AML) who are eligible for intensive chemotherapy. The main goals are to find the safest dose of this triple-drug reg…
Matched conditions: IDH1 MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug combo aims to control tough leukemia with fewer side effects
Disease control Recruiting nowThis study is testing a combination of three drugs (olutasidenib, venetoclax, and azacitidine) for adults newly diagnosed with a specific type of acute myeloid leukemia (AML) that has an IDH1 mutation. The main goals are to see if this combination is safer and works better than t…
Matched conditions: IDH1 MUTATION
Phase: PHASE2 • Sponsor: Justin Watts, MD • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope to keep leukemia at bay after transplant
Disease control Recruiting nowThis study is testing whether a drug called ivosidenib can help prevent a specific type of leukemia (AML with an IDH1 mutation) from coming back after a patient has received a stem cell transplant. About 75 participants will be randomly assigned to receive either the study drug o…
Matched conditions: IDH1 MUTATION
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Feb 27, 2026 15:06 UTC